Y-mabs announces u.s. fda acceptance of biologics license application for danyelza(naxitamab)

Y-mabs announces u.s. fda acceptance of biologics license application for danyelza™ (naxitamab) for the treatment of neuroblastoma for priority review.y-mabs therapeutics, - fda set an action date of november 30, 2020, under prescription drug user fee act for danyelza.y-mabs therapeutics - agency indicated in bla filing communication letter it is not planning to hold advisory committee meeting to discuss application.
YMAB Ratings Summary
YMAB Quant Ranking